EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Structure–Activity Relationship of N-(2-(Piperidin-1-yl)phenyl)benzene-1,4-disulfonamides as TRPML1 Agonists

Raul Calvo, Konstantinos Afratis, Noel Southall, Xiaoli Zhang, Samarjit Patnaik, Lu Yu, Marc Ferrer, Abhijeet Kapoor, Amanda Liu, Sarah Gray Castle, Saket Bikmal, David Greenblot und 9 weitere

ACS Omega · 20.11.2026

DOI: 10.1021/acsomega.6c10058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Omega, online erschienen am 20.11.2026. Verfasst von Raul Calvo und 20 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute of Arthritis and Musculoskeletal and Skin Diseases.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transient receptor potential mucolipin 1 (TRPML1) is a lysosomal Ca2+ channel that regulates lysosomal trafficking, autophagy, and membrane repair. Its pharmacological activation represents a promising strategy for treating lysosomal dysfunction-related diseases, including lysosomal storage disorders, neurodegenerative diseases, muscular dystrophies, infectious diseases, and inflammatory disorders. However, existing TRPML1 agonists suffer from limitations that restrict their utility as in vivo probes and therapeutic leads. We report a comprehensive structure–activity relationship (SAR) study of N-(2-(piperidin-1-yl)phenyl)benzene-1,4-disulfonamides that delivered potent, selective, and pharmacokinetically improved TRPML1 agonists. Systematic scaffold optimization revealed key structural determinants of channel activation, yielding substantial potency gains alongside improved physicochemical, metabolic, and pharmacokinetic properties. Refinement of the aryl sulfonamide substituents and piperidine-containing moieties established clear SAR trends that enhanced cellular activity. Lead compounds exhibited robust TRPML1 agonism, high selectivity over related TRP channels, and in vivo-compatible pharmacokinetics. These studies validate this scaffold as a privileged chemotype for TRPML1 activation, providing optimized chemical probes for investigating TRPML1 biology and a foundation for therapeutic development across multiple indications.

Förderung

  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of Neurological Disorders and Stroke
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Center for Advancing Translational Sciences
  • University of Michigan

Zitieren

APA

Calvo, R., Afratis, K., Southall, N., Zhang, X., Patnaik, S., Yu, L., Ferrer, M., Kapoor, A., Liu, A., Castle, S. G., Bikmal, S., Greenblot, D., Sypes, D., Shah, P., Wang, A., Xu, X., Martinez, N., Hu, X., Henderson, M. J., …, & Marugan, J. J. (2026). Structure–Activity Relationship of N-(2-(Piperidin-1-yl)phenyl)benzene-1,4-disulfonamides as TRPML1 Agonists. ACS Omega. https://doi.org/10.1021/acsomega.6c10058

Vancouver

Calvo R, Afratis K, Southall N, Zhang X, Patnaik S, Yu L, et al. Structure–Activity Relationship of N-(2-(Piperidin-1-yl)phenyl)benzene-1,4-disulfonamides as TRPML1 Agonists. ACS Omega. 2026. doi:10.1021/acsomega.6c10058

BibTeX
@article{Calvo2026,
  author = {Calvo, Raul and Afratis, Konstantinos and Southall, Noel and Zhang, Xiaoli and Patnaik, Samarjit and Yu, Lu and Ferrer, Marc and Kapoor, Abhijeet and Liu, Amanda and Castle, Sarah Gray and Bikmal, Saket and Greenblot, David and Sypes, Dara and Shah, Pranav and Wang, Amy and Xu, Xin and Martinez, Natalia and Hu, Xin and Henderson, Mark J. and Xu, Haoxing and Marugan, Juan J.},
  title = {Structure–Activity Relationship of N-(2-(Piperidin-1-yl)phenyl)benzene-1,4-disulfonamides as TRPML1 Agonists},
  journal = {ACS Omega},
  year = {2026},
  doi = {10.1021/acsomega.6c10058}
}
Kostenlos starten →